TERNS PHARMACEUTICALS INC's ticker is TERN and the CUSIP is 880881107. A total of 43 filers reported holding TERNS PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,838,365 | -59.2% | 167,480 | -67.5% | 0.22% | -69.3% |
| Q2 2023 | $4,510,451 | -47.2% | 515,480 | -28.5% | 0.72% | -62.9% |
| Q1 2023 | $8,540,677 | +13.8% | 721,341 | -2.2% | 1.94% | +7.0% |
| Q4 2022 | $7,505,908 | +40.9% | 737,319 | -18.4% | 1.81% | +70.7% |
| Q3 2022 | $5,326,000 | +206.8% | 904,119 | +29.2% | 1.06% | +234.7% |
| Q2 2022 | $1,736,000 | – | 700,000 | – | 0.32% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 6,657,992 | $33,489,700 | 3.67% |
| ACUTA CAPITAL PARTNERS, LLC | 555,260 | $2,792,958 | 1.87% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 6,041,910 | $30,390,807 | 1.64% |
| VR Adviser, LLC | 3,092,273 | $15,554,133 | 1.64% |
| Fairmount Funds Management LLC | 2,040,000 | $10,261,200 | 1.24% |
| Decheng Capital Management III (Cayman), LLC | 714,285 | $3,592,854 | 1.20% |
| Deep Track Capital, LP | 6,000,000 | $30,180,000 | 1.16% |
| Orbimed Advisors | 7,619,135 | $38,324,249 | 0.81% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 500,000 | $2,515,000 | 0.76% |
| GREAT POINT PARTNERS LLC | 645,899 | $3,248,872 | 0.59% |